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Abstract: Childhood obesity has become a national and international epidemic. The prevalence 
and incidence of type 2 diabetes in youth have been increasing, and type 2 diabetes is one of the 
most challenging complications of obesity in childhood. Comprehensive lifestyle interventions 
that include attention to dietary change, increased physical activity and behavior change appear 
to be required for the successful treatment of pediatric obesity. In particular, aspects of behavioral 
interventions that have been identified as contributing to effectiveness have included intensity, 
parent/family participation, addressing healthy dietary change, promoting physical activity, 
and involving behavioral management principles such as goal setting. A multidisciplinary team 
approach is required for successful management of type 2 diabetes in youth as well. As with 
many therapies in pediatrics, clinical trials and support for treatments of obesity and type 2 
diabetes in youth lag behind adult data. Pediatric recommendations may be extrapolated from 
adult data and are often based on consensus guidelines. Type 2 diabetes in children is most 
commonly managed with lifestyle modification and medications, metformin and/or insulin, the 
only medications currently approved for use in children. However, many opportunities exist for 
ongoing research to clarify optimal management for obesity and type 2 diabetes in youth.
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Introduction
Childhood obesity has become a national and international epidemic. This may be the 
greatest threat to the health of today’s children and, if predictions hold true, may result 
in the first reduction in average lifespan for the current generation.1 The causes of the 
obesity epidemic are complex, and the treatments must therefore be comprehensive. 
In this review, we discuss management strategies for obesity, insulin resistance, 
and type 2 diabetes mellitus in childhood, and highlight some of the unresolved 
controversies in this therapeutic area.
Obesity
Childhood obesity is a worldwide epidemic.2 Given the global nature of the problem, 
the definition of obesity may also take on different meaning depending on the location. 
In the US, overweight in children is currently defined as a body mass index (BMI), 
weight in kilograms divided by the square of the height in meters, that is at or above 
the 85th percentile for age and sex but below the 95th percentile, and obesity is defined 
as a BMI that is at or above the 95th percentile for age and sex.3 The reference data are 
the 2000 sex-specific BMI for age growth charts from the Centers for Disease Control 
and Prevention.4 However, in other parts of the world, different reference data or Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 186
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cut-offs may be used. To facilitate international comparisons, 
Cole et al have suggested age-specific BMI cut-offs based 
on international data that are linked to the adult cut-offs of 
25 kg/m2 for overweight and 30 kg/m2 for obesity.5
In the US, a periodic population-based survey, the 
National Health and Nutrition Examination Survey 
(NHANES), has been used to monitor the prevalence of 
overweight and obesity among children. Data from NHANES 
surveys from 1976–1980 to 2003–2006 showed that the 
prevalence of obesity increased 2- to 3-fold. Among children 
aged 2 to 5 years, the prevalence increased from 5.0% to 
12.4%; among 6- to 11-year-olds, prevalence increased from 
6.5% to 17.0%; and among 12- to 19-year-olds, prevalence 
increased from 5.0% to 17.6%.6,7 These worrisome trends 
also portend an increase in children at risk for complications 
including insulin resistance, type 2 diabetes, hypertension, 
dyslipidemia, and fatty liver3,8 as well as increased morbid-
ity as adults.9,10
Obesity-related comorbidities
Multiple medical problems are associated with pediatric 
obesity including insulin resistance and type 2 diabetes 
mellitus. Other problems include dyslipidemia and hyperten-
sion as well as polycystic ovary syndrome, steatohepatitis, 
obstructive sleep apnea, orthopedic complications, and 
mental illness, especially depression. In this review, we will 
focus on insulin resistance and type 2 diabetes. Although 
not discussed in detail in this review, recent consensus 
statements on screening, therapeutics and follow up in 
children with altered lipid parameters11 and hypertension12 
are available. Evaluation of children for obesity must include 
consideration and evaluation of these associated medical 
problems.
insulin resistance and the metabolic 
syndrome
Metabolic syndrome, also termed the dysmetabolic syndrome, 
syndrome X or the insulin resistance syndrome, is a group of 
related risk factors associated with obesity and type 2 diabetes, 
which is predictive of cardiovascular disease in adults.13–16 The 
elements include measures of adiposity, lipids, glucose and 
blood pressure. There are several definitions of this syndrome 
in adulthood including those from the World Health Organi-
zation,13 the National Cholesterol Education Program,14 and 
the International Diabetes Federation.15 More recently, the 
American Heart Association (AHA) and the National Heart, 
Lung and Blood Institute (NHLBI) modified the glucose 
parameters used in their definition of the metabolic syndrome 
to be more inclusive.16 There is a lack of consensus in the 
pediatric literature about the elements, the pediatric cut-offs 
and the clinical relevance of this syndrome in children. Some 
have applied the adult cut-offs in the pediatric age range.17 
However, most pediatric investigators have endorsed pediatric 
specific cut-offs such as those proposed by de Ferranti and 
others,18 based on the NHANES data. These include: waist 
circumference 75th percentile for age and sex; systolic 
or diastolic blood pressure for age, sex and height 90th 
percentile; triglycerides 100 mg/dL; high-density lipoprotein 
(HDL) for boys 15 to 19 years old 45 mg/dL; and HDL 
for all others 50 mg/dL; and fasting glucose 110 mg/dL. 
Several other similar criteria for the pediatric population 
have been proposed.19–21 However, regardless of the specific 
definition, it remains to be determined to what extent these 
metabolic abnormalities, as a group, may represent a state 
of increased risk for progression to type 2 diabetes and 
cardiovascular disease in children.22,23 Therefore, this review 
focuses on obesity and insulin resistance as well as type 2 
diabetes mellitus. It is difficult to focus on a single meta-
bolic complication as the lack of consensus definition leads 
to variable research endpoints. However, there is consensus 
that one of the key approaches to managing these metabolic 
abnormalities is to promote reduction in BMI using therapies 
for obesity as outlined below. Identifying the risk factors asso-
ciated with the metabolic syndrome can guide the intensity 
and breadth of the interventions prescribed.
Type 2 diabetes
Type 2 diabetes mellitus refers to a nonautoimmune form 
of diabetes characterized by insulin resistance and relative 
insulin deficiency. Almost unheard of in children only a 
few decades ago, the epidemic of childhood obesity has 
contributed to a progressive increase in the incidence and 
prevalence of type 2 diabetes in the US and around the 
world.24–31 In absolute terms, the overall number of children 
with type 2 diabetes remains relatively small in many parts of 
the world. For example, a recent study from the UK reported 
a prevalence of type 2 diabetes in children less than 17 years 
of age of 0.21 per 100,000 or approximately 1 per 500,000.31 
However, recent estimates of the prevalence and incidence 
of type 2 diabetes in children in the US are several fold higher 
than those in Europe.32 In the US, the SEARCH for Diabetes 
in Youth Study, which began in 2000, has provided the most 
comprehensive estimates of the prevalence and incidence of 
type 2 diabetes among youth less than 20 years of age in the 
US. The prevalence of type 2 diabetes among 10- to 19-year-
old youth ranged from 0.18/1000 (approximately 1 in 5600) Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 187
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for non-Hispanic White youth to 1.45/1000 (approximately 
1 in 700) for Navajo youth, and the incidence ranged 
from 3.7/100,000/year for non-Hispanic White youth to 
27.7/100,000/year for Navajo youth.32,33 Prevalence and 
incidence of type 2 diabetes for Black, Hispanic, Asian, 
and Pacific Islander US youth are intermediate.34–36 The 
incidence of type 2 diabetes is also increasing in the UK, 
and children of ethnic minorities are also at higher risk with 
Blacks and those of South-Asian origin (in England) having 
an incidence of 3.9 and 1.25/100,000/year, respectively, 
compared with 0.35/100,000/year in White children.29 In 
Tokyo, the incidence of type 2 diabetes in children has 
also been increasing with a rate of 2.76/100,000/year 
since 1981 compared to 1.73/100,000/year before 1980.26 
Ongoing research will be needed to monitor these patterns.
Management of obesity and insulin 
resistance
Lifestyle modification
Several recent guidelines for the management of pediatric 
obesity3,37 have stressed that comprehensive lifestyle inter-
ventions, that include attention to dietary change, increased 
physical activity and behavior modification, are required for 
the successful treatment of pediatric obesity. Understanding 
the individual contribution of each of these therapies to the 
overall success of the intervention has been the focus of 
ongoing research.
With regard to dietary interventions, a recent Cochrane 
review of interventions for treatment of obesity in children, 
identified only 6 studies (4 in children less than 12 years 
old and 2 in children 12 years and older) that met the 
review criteria.38 Criteria for inclusion in the review for 
lifestyle interventions included randomized controlled 
trials that were specifically designed to evaluate the impact 
of obesity treatment in children or adolescents with at least 
6 months’ duration.38 Other systematic reviews of interven-
tions for pediatric obesity have similarly demonstrated 
few high-quality studies addressing this issue.39,40 Given 
the emphasis on a multidisciplinary approach to pediatric 
weight management, few studies have been designed to 
specifically evaluate the impact of the dietary component of 
the intervention. Collins et al40 reported a meta-analysis of 
8 studies that included a dietary component and an adequate 
control group that was either no intervention, waiting list 
or usual care. They found that studies including a dietary 
component effectively achieved relative weight loss among 
overweight/obese children and adolescents. However, further 
analysis of a subset with longer follow up demonstrated a 
loss of some of these benefits over time. Maintenance support 
following an intensive intervention may be required for long-
term success.41
Recent guidelines on management of pediatric obesity 
have concluded that evidence is insufficient to recommend 
one specific diet over another.3,37 One comparison of interest 
has focused on the benefits of a low fat vs a low glycemic 
index diet. Other studies have also evaluated a protein-
sparing modified diet, high-protein diet, or energy restricted 
interventions. The Cochrane review commented on one 
adolescent study by Ebbeling et al42 which demonstrated that, 
after 12 months, subjects on an ad libitum low glycemic load 
diet lost significantly more weight than those on an energy 
restricted low fat diet (a difference of 2 BMI units, n = 16, 
P  0.05). Amongst the studies included in the meta-analysis 
by Collins et al, Saelens et al43 evaluated a 4-month behavioral 
weight control program for overweight adolescents initiated 
in a primary care setting compared to a single session of 
physician weight counseling. The dietary recommenda-
tions within the intervention were aimed at fat and calorie 
reduction. Adolescents in the treatment group were found to 
have modest reduction in BMI z-score whereas those in the 
control had an increase in BMI z-score. Further, 40% of the 
treatment group achieved reduction in BMI z-score vs 10.5% 
in the control group (P  0.04). Further studies comparing 
dietary interventions while maintaining other aspects of 
the intervention constant, such as behavioral support and 
physical activity recommendations, are needed. At present, 
general dietary guidelines include avoiding consumption 
of calorie-dense, nutrient-poor foods; reducing intake of 
dietary saturated fat and increasing intake of dietary fiber, 
fruits and vegetables.37
Exercise has been recognized as an essential component 
of treatment for obesity, insulin resistance and type 2 diabetes 
in children. The Centers for Disease Control and Prevention 
recommend that children perform 60 minutes of exercise 
daily to promote health and reduce the risk of obesity and its 
complications.44 The type, duration and schedule of exercise 
recommended for children remain an area of controversy. 
Furthermore, as suggested in the Cochrane review,38 the 
comparability of different exercise interventions is often 
unclear, and therefore the efficacy of exercise as a treatment 
for pediatric obesity remains difficult to formally evaluate 
in children.
A systematic review of the impact of resistance training 
on metabolic fitness in children was conducted in 2008 and 
found a total of 12 relevant studies.45 The majority of reported Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 188
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studies were relatively short, between 6 and 10 weeks in 
duration, and with 1 to 5 days of supervised activity per 
week. In most studies, metabolic outcomes were evaluated 
by fasting lipid panels, fasting insulin and glucose levels 
and were unchanged by the intervention. In contrast, there is 
ample evidence that resistance training in adults can reduce 
insulin resistance, and reduce the incidence of type 2 diabetes 
in high risk adults.46 
More data are available on the specific impact of aerobic 
exercise on overweight/obese children. In a study of 19 over-
weight and obese adolescent girls, Nassis et al showed that 
aerobic training for 12 weeks was able to reduce the insulin 
area under the curve based on oral glucose tolerance testing 
by 23.3% without changes in body weight or percent body 
fat.47 Similarly, a school-based aerobic fitness intervention 
of 50 obese middle school age children demonstrated a loss 
of body fat, increase in cardiovascular fitness, and improve-
ment in fasting insulin levels in the treated compared to 
control subjects over 9 months.48 Finally, Bell et al showed 
improvement in insulin sensitivity by hyperinsulinemic 
euglycemic clamp after an eight week mixed aerobic and 
resistance training intervention in a small study of obese, 
insulin-resistant children without changes in body weight 
or body composition.49 However, the benefit of exercise 
alone on weight reduction in children remains in question. 
The recent Cochrane analysis suggested that family-based 
lifestyle interventions with a behavioral program targeting 
physical activity as well as dietary change can be successful 
in treatment of pediatric obesity.38 The results of interventions 
specifically targeting physical activity on short- and long-
term weight loss were variable.38 However, the benefit of 
regular exercise on some metabolic parameters, including 
insulin resistance, was clear even in the setting of lack of 
weight changes (Table 1).
Table 1 Studies of interventions influencing insulin resistance in children: exercise and metformin
References Size and subjects Study design Intervention Duration Primary outcome
Exercise  
interventions
Bell et al49 14 obese  
(BMi  95th %),  
9 to 16 years old
Open, single arm Mixed aerobic 
and resistance 
training, 3, 1-hour 
sessions per week, 
hyperinsulinemic 
euglycemic clamp
8 weeks improved insulin sensitivity 
by clamp
Nassis et al47 19 overweight girls 
(BMi  85th %),  
9 to 15 years old
Open, single arm Aerobic training, 
40 minutes, 3 days 
per week, OGTT
12 weeks Reduced insulin AUC,  
no change in fasting insulin 
and HOMA-iR
Carrel et al48 50 obese  
(BMi  95th %) 
middle school 
students
Randomized, controlled School-based small 
fitness classes, 
fasting laboratory 
studies
9 months Reduced fasting insulin
Metformin
Freemark et al57 29 obese  
(BMi  30 kg/m2), 
elevated fasting 
insulin and family 
history of type 2  
diabetes mellitus, 
12–19 years old
Double-blind, randomized, 
controlled
Metformin 500 mg 
or placebo twice 
daily, FSivGTT
6 months improved fasting glucose 
and insulin levels, 
no significant improvement 
in insulin sensitivity 
parameters by minimal 
model analysis
Atabek et al60 120 obese  
(BMi  95th %),  
9–17 years old
Double-blind, randomized, 
3:1, controlled
Metformin 500 mg 
or placebo twice 
daily, OGTT
6 months improved fasting insulin, 
120-minute insulin,  
HOMA-iR
Srinivasan et al59 22 obese and 
insulin resistant,  
9–18 years old
Double-blind, randomized 
to metformin or placebo 
for cross over, controlled
Metformin 1 g twice 
daily, FSivGTT
12 months  
(6 months each 
intervention)
improved fasting glucose 
and insulin, no significant 
improvement in insulin 
sensitivity parameters by 
minimal model analysis
Abbreviations:   AUC, area under the curve; FSivGTT, frequently sampled intravenous glucose tolerance test; HOMA-iR, homeostasis model assessment–insulin resistance; 
OGTT, oral glucose tolerance test.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 189
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A variety of behavioral approaches to address pediatric 
obesity have been proposed.38,39 The heterogeneity of the 
interventions has made identifying the importance of specific 
aspects or approaches difficult in systematic reviews.39 
However, aspects of behavioral interventions that have been 
identified as contributing to effectiveness have included 
intensity, parent/family participation, addressing healthy 
dietary change, promoting physical activity, and involving 
behavioral management principles such as goal setting.39 
However, in clinical practice, high rates of attrition in 
multidisciplinary and family-based treatment programs 
for pediatric obesity have been documented with estimates 
as high as 34% to 64% of families.50,51 Additional research 
is still needed to understand how to make effective interven-
tions more generalizable. Behavioral interventions are an 
essential component of a comprehensive lifestyle modification 
program and the intervention itself must be flexible enough 
to adjust to individual and family needs.
Medical intervention
Pharmacologic therapies for the treatment of obesity remain 
an area of intense scientific interest. Although there are 
now several categories of approved medical therapies in 
adults, there are limited studies in children and adolescents 
addressing their safety and efficacy. A recent meta-analysis 
performed for The Endocrine Society52 determined that there 
were 17 pediatric trials of pharmacologic agents for treatment 
of pediatric obesity. These included trials of sibutramine, 
orlistat and metformin as well as a smaller number of trials 
evaluating sympathomimetics, dehydroepiandrosterone, 
and fiber supplements. This meta-analysis included fully 
published trials of any duration through February 2006. 
A more recent meta-analysis of metformin for treatment 
of pediatric obesity included trials of at least 6 months 
duration through December 2008.53 Discussion of metformin, 
sibutramine and orlistat are presented separately below. 
Each of these medications may have a role in selected high 
risk populations of obese adolescents in conjunction with 
intensive lifestyle modification (Table 2).
Metformin
Metformin is an oral hypoglycemic agent that is approved 
in the pediatric population (age 10 years and older) for 
the treatment of type 2 diabetes. It is a biguanide, and its 
primary action is to reduce hepatic glucose production and 
to secondarily improve peripheral insulin sensitivity. It is not 
currently approved for use in obesity or insulin resistance 
in adolescents, and its use for these indications has been 
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an area of debate. Interest in metformin for obesity arises 
from its success in adult studies, most notably the Diabetes 
Prevention Program,54 which demonstrated a 31% reduc-
tion in risk of type 2 diabetes among high risk adults with 
metformin therapy. Use of metformin to treat obesity-related 
comorbidities associated with insulin resistance, such as 
polycystic ovarian syndrome (PCOS)55 and nonalcoholic 
steatohepatitis,56 has also been under investigation.
The two small meta-analyses of randomized trials 
of metformin therapy in pediatrics used overlapping but 
not equivalent sets of studies and arrived at differing 
conclusions. The earlier meta-analysis by McGovern et al of 
three trials57–59 of metformin monotherapy therapy in obese 
hyperinsulinemic adolescents showed no significant change 
in BMI at 6 months (SMD –0.17, 95% CI –0.62, 0.28).52 
More recently, Park et al conducted a meta-analysis of the 
320 individuals in 5 trials57,59–62 of at least 6 months’ duration, 
using 1000 to 2000 mg of metformin daily and concluded 
that metformin reduced BMI by 1.42 kg/m2 (95% CI 0.83, 
2.02) and reduced insulin resistance assessed by HOMA-IR 
while showing minimal changes in fasting insulin, glucose, 
cholesterol levels and blood pressure.53
Studies included in both meta-analyses included those by 
Freemark et al57 and Srinivasan et al.59 Both studies had primary 
endpoints of weight and insulin resistance. Freemark et al57 
evaluated 29 obese adolescents with fasting hyperinsulinemia 
and a family history of type 2 diabetes in a 6-month, double-
blind, placebo-controlled trial. Treated subjects received 
metformin 500 mg twice daily and showed a reduction in 
BMI (–0.5 kg/m2) and BMI SDS (–0.12) and improved insulin 
sensitivity. Srinivasan et al59 studied 28 children, ages 9 to 
18 years, who received metformin 1000 mg twice daily or 
placebo for 6 months, with a 2 week wash out between each 
intervention. They found metformin had a greater treatment 
effect over placebo for weight (–4.35 kg, P = 0.02), body mass 
index (–1.26 kg/m2, P = 0.002), waist circumference (–2.8 cm, 
P = 0.003), abdominal adipose tissue (–52.5 cm2, P = 0.002), 
and fasting insulin (–2.2 mU/L, P = 0.011). In another small 
8 week trial of metformin 850 mg twice daily compared to 
placebo, Kay et al58 showed a small but significant reduction in 
BMI, as well as lipid parameters among 24 hyperinsulinemic 
obese adolescents. Other more recent studies have also demon-
strated improvements in both insulin sensitivity and reduction 
in BMI among metformin-treated obese children and adoles-
cents.60,63 One60 used insulin resistance as a primary endpoint. 
Thus, small studies demonstrate improvements in insulin 
sensitivity and other metabolic factors, with small reduc-
tions in BMI or weight and, when pooled, a subset showed 
significant reductions in BMI in one meta-analysis. The studies 
demonstrated limited safety concerns, with the most common 
side effect being gastrointestinal with resolution with dose 
reduction.57,59 The three studies with insulin resistance as a 
primary outcome are outlined in more detail in Table 1.
Metformin has also been shown to reduce visceral fat, 
insulin resistance and hyperandrogenism in a population 
of girls from Spain, who are both of low birth weight and 
develop premature adrenarche. The use in these girls in 
prepuberty appears to modify some of the pathologic changes 
in glucose metabolism and body composition that accompany 
puberty.64–66 Although extremely encouraging, the general-
izability of these findings to other populations remains an 
area of investigation.
Sibutramine
Sibutramine is a serotonin and norepinephrine reuptake 
inhibitor. Sibutramine is currently approved for use in 
the United States in adolescents over the age of 16 years. 
Three randomized placebo-controlled trials of sibutra-
mine in adolescents were pooled in a meta-analysis52 and 
demonstrated a significant loss of BMI of 2.4 kg/m2 (95% CI 
1.8, 3.1) after 6 months. The first study, by Berkowitz et al,67 
enrolled 82 children who were randomized to sibutramine 
or placebo for 6 months followed by a 6-month, open-label 
sibutramine extension phase. The medication therapy was 
used in combination with a behavioral protocol including 
group meetings for participants and families, recommenda-
tions for a low calorie diet and exercise. The sibutramine 
group had a significantly greater reduction in BMI (8.5% vs 
4.0%) compared to the placebo-treated group at 6 months. 
There was evidence of increase in blood pressure and heart 
rate in the children treated with sibutramine. In fact, 19 of 
43 children had the medication reduced (from 15 mg to 
10 or 5 mg) or discontinued due to alterations in blood 
pressure or heart rate during the trial. Godoy-Matos et al68 
conducted a randomized, double-blind, placebo-controlled 
study with 60 adolescents treated for 6 months with sibutra-
mine (10 mg daily) as well as a hypocaloric diet and exercise 
recommendations given at the initiation of the study. This 
study demonstrated a significantly greater reduction in BMI in 
the sibutramine group (3.6 vs 0.9 kg/m2). The difference in 
the change in weight and BMI became significant at 4 weeks 
and remained so for the duration of the 6-month intervention. 
Almost half (46.6%) of the adolescents in the sibutramine 
group reduced their weight by 10%. Participants had 
echocardiograms at baseline and completion of the study 
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in glucose or insulin values. However, there were favorable 
changes in lipid parameters in this study. Importantly, this 
study did not include an intensive behavioral management 
plan and may therefore be more representative of a standard 
clinical scenario. In addition, although smaller, this study 
did not demonstrate significant changes in blood pressure or 
heart rate. A small study69 evaluated BMI and body composi-
tion by underwater weighing and dual X-ray absorptiometry. 
The 24 subjects received sibutramine (10 mg) or placebo 
plus an energy restricted diet and exercise plan for 12 weeks. 
The study found no differences in BMI or body composi-
tion between the two groups at study completion. Therefore, 
the absolute effect size of the addition of sibutramine to a 
standard or intensive weight loss program remains an area 
of controversy. The Sibutramine Adolescent Study Group 
has performed the largest studies addressing the efficacy and 
safety of this medication. Published in 2006,70 this multicenter 
trial enrolled 498 children, ages 12 to 16 years, for a 12-month 
trial of sibutramine (10–15 mg) or placebo, plus a behavior 
therapy program including lifestyle modification. Completion 
rates were 72% in the sibutramine group and 62% in the 
placebo group. The sibutramine group had a significant 
reduction in BMI (–2.9 vs –0.3 kg/m2). Almost half of the 
participants (45.6%) had a 10% reduction in BMI in the 
sibutramine group compared to 6.3% in the placebo group. 
In addition, lipid parameters and insulin levels improved in 
the medication group. Therefore, this large study supported 
the efficacy of this medication over behavioral therapy 
alone, but the treatment effect of the entire intervention 
remained small. The same group published a safety evaluation 
addressing the cardiovascular effects of the treatment in this 
group.71 In the medication-treated group, 13% experienced 
tachycardia compared to 6% in the placebo-treated group. 
However, the study found no statistically significant differ-
ences in blood pressure between groups, and both groups 
showed small reductions in blood pressure parameters 
in association with weight loss. However, children with 
hypertension and tachycardia were excluded from the study. 
Of note, the FDA recently added additional warnings to the 
labeling of sibutramine to include the potential for serotonin 
syndrome, especially in association with the use of selective 
serotonin reuptake inhibitors (SSRIs), monoamine oxidase 
inhibitors (MAOIs), serotonergic drugs such as triptans or 
some antipsychotics, but also when used alone.
Orlistat
Orlistat, a gastrointestinal tract lipase inhibitor, can decrease 
the intestinal fat absorption by up to 30%. This has been the only 
approved therapy for adolescent obesity (ages 12–16 years) 
since December of 2003. Three randomized clinical trials of 
orlistat therapy pooled in a meta-analysis52 demonstrated a 
significant reduction in BMI of 0.7 kg/m2 (95% CI 0.3, 1.2). 
In 2002, a small open-label study of 20 participants treated 
for 6 months in association with a lifestyle modification 
program was completed.72,73 Children with morbid obesity 
(mean BMI of 44.1 kg/m2) plus a comorbidity were enrolled. 
The 3-month72 and 6-month73 data revealed a significant 
reduction in BMI of 1.9 and 2 kg/m2, respectively, as well as 
improvements in lipids, insulin and glucose levels. Norgren 
et al74 and Ozkan et al75 performed small clinical trials 
of 4 to 15 months’ duration and demonstrated significant 
weight reduction of similar magnitude but also called attention 
to the gastrointestinal side effects of orlistat in children and 
adolescents. One double-blind, placebo-controlled, 6-month 
clinical trial in 40 participants, performed by Maahs et al76 
demonstrated no significant difference in BMI between the 
medication and placebo groups.
By far the largest trial has been a large multicenter, 
randomized, double-blind study of 539 adolescents published 
in 2005.77 Enrollment criteria included age 12 to 16 years and 
BMI  2 units or higher than the 95th percentile for age and 
sex. Participants were excluded for a BMI of greater than 
44 kg/m2, recent weight loss, diabetes or obesity-related 
medications or syndromes. The study medication, orlistat 
120 mg 3 times daily or placebo, was given for 52 weeks, 
in addition to a hypocaloric diet, behavioral modification, 
and exercise counseling. Completion rates were 65% and 
64% in the medication and placebo groups respectively. 
At completion of the study, the participants in the orlistat-
treated group had decreased the BMI from baseline by 
0.55 kg/m2, while the placebo-treated group had increased 
by 0.31 kg/m2. Although these values were significantly 
different, the mean change in kilograms in the treated group 
was essentially zero at the completion of the study. However, 
the orlistat-treated participants did regain less weight than 
the placebo-treated participants. Furthermore, the orlistat-
treated group also had a significantly greater decrease in 
waist circumference and body fat compared to placebo, 
although there were no significant differences in lipid, 
glucose or insulin levels. Over 50% of the orlistat-treated 
participants had gastrointestinal side effects, although only 
2% discontinued therapy. Concern about malabsorption is 
heightened in adolescents, who require sufficient vitamins 
for completion of growth, development and bone accrual. 
Orlistat directly reduces the absorption of fat soluble 
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or specific supplementation of fat soluble vitamins.73 Even 
with supplementation, as recommended by the FDA, some 
participants demonstrated reductions in fat soluble vitamins, 
particularly vitamin D.78 Overall, orlistat shows some efficacy 
in reducing BMI in obese adolescents. Gastrointestinal side 
effects are common, and fat soluble vitamin levels should 
be supplemented and monitored during therapy.
Taken together, these studies suggest that metformin may 
have efficacy in targeting insulin resistance in adolescents 
and may contribute to short-term weight loss. The long-
term benefit remains unclear. There are also some data to 
support the efficacy of both sibutramine and orlistat for BMI 
reduction in selected high risk adolescents in association 
with a comprehensive weight loss program. As suggested by 
recent expert consensus guidelines,3,37 pharmacologic therapy 
should only be prescribed by clinicians experienced in the 
use of these medications and the associated monitoring that 
is required. Further, these treatments should be considered 
only when aggressive lifestyle intervention alone has been 
unsuccessful in weight management and in the prevention 
or resolution of obesity-related comorbidities.
Bariatric surgery
Bariatric surgery has been shown to improve both obesity 
and obesity-related comorbidities when utilized in the adult 
population to treat morbid obesity with complications.79 
The data in children are more limited. An ongoing effort 
by the National Institute of Diabetes and Digestive and 
Kidney Diseases (NIDDK), National Institutes of Health, 
the Teen-Longitudinal Assessment of Bariatric Surgery, 
will serve as the first study to investigate safety and effi-
cacy in a large cohort of adolescents undergoing bariatric 
surgery at multiple centers. To date, published reports are 
limited in number of participants and duration of follow up. 
However, a meta-analysis of the current data80 indicates a 
36% reduction in BMI by 5 years postoperatively. These 
are similar to the data reported in the adult population. 
Furthermore, recent studies suggest that surgical weight 
loss may cause improvements or remittance of diabetes 
mellitus, as has been seen in adult studies.81 Although these 
studies are few, the mechanism in adults appears to be the 
surgical process and not the degree of weight loss suggesting 
similar improvements may occur in adolescents with type 2 
diabetes. Importantly, preliminary adolescent studies also 
demonstrate that quality of life and depression measures 
improve in the year following surgical weight loss.82 
Complication rates in adolescents are similar83 or lower84 
compared to those in adults although adolescent surgeries of 
this type make up a small portion of the surgeries conducted 
annually in the US (1% in 2003).
The current options for bariatric surgery include 
adjustable banding, gastric bypass with Roux-en-Y, gastric 
sleeve and biliopancreatic bypass with duodenal switch. The 
standard of care for adolescents is the gastric bypass surgery, 
as the adjustable band is only FDA approved for individuals 
over the age of 18 years. However, a number of centers are 
able to perform the adjustable banding and, in one survey 
about procedure preference,85 a majority chose the gastric 
band procedure for adolescents due to the noninvasive 
nature of the surgery and the ability to noninvasively adjust 
the band. Gastric banding does reduce the risks of vitamin 
deficiencies. However, the reoperation rates, including band 
removal, are high (8%–10%),86,87 and therefore the safety of 
both surgeries should be considered. Other procedures are 
currently in the investigational stage for adolescents. The 
efficacy and safety of each procedure in this population will 
be better understood after the accumulation of additional 
data. Thus, it remains premature to recommend one method 
for use in the adolescent population.
There are several important considerations regarding 
the use of bariatric surgery in adolescents. Age and ongoing 
linear growth must be considered as should the child’s 
maturity and psychological appropriateness for a procedure 
that will require lifelong change in dietary habits.3,37 
In addition, candidates for surgical procedures must be 
evaluated in the context of the family. Adolescents are 
particularly at risk for nutrient deficiencies, including iron, 
vitamin D and calcium,88,89 and weight loss surgery can 
result in worsening of these deficiencies.90 As adolescence is 
an essential time period for bone accrual, these deficiencies 
should be avoided and thus surgical candidates must 
agree to closely comply with nutritional guidelines and 
supplementation. All participants must have a thorough 
medical and psychological evaluation prior to the procedure 
to evaluate the preparedness of the patient and family.3,37,91 
Contraindications include lack of supportive home structure, 
substance abuse, pregnancy or significant risk of pregnancy, 
or medical syndrome underlying the obesity that could be 
further evaluated. Psychological illness, such as depression, 
should be evaluated and appropriately treated prior to the 
procedure. Due to the frequent co-occurrence of mental 
illness in obesity, comprehensive evaluation must be 
performed with each individual to determine capacity for 
compliance with the pre-operative, operative and post opera-
tive protocols. In addition, the determination of adequate Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 193
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treatment for mental illness should be assessed by an 
appropriately trained mental health provider familiar with 
the procedure and necessary compliance.
Consensus guidelines for use of bariatric surgery in 
obese adolescents are available.3,37,91 Recommendations 
were developed after expert reviewers performed systematic 
searches of the literature with evidence grading scales 
to support recommendations. These panels suggest that 
adolescents should be considered for surgical therapy only 
after failure of an age appropriate, multidisciplinary weight 
management treatment of at least 6 months in duration. 
The details of such a program, as addressed in this review, 
remain an area of debate in the field. Appropriate patients 
would have morbid obesity, BMI of greater than or equal 
to 40 kg/m2 with other comorbidities, or over 35 kg/m2 
plus serious comorbidities such as type 2 diabetes mellitus, 
severe steatohepatitis, severe sleep apnea, or pseudotumor 
cerebri.91 The use of numerical cut-offs in lieu of percentiles 
in adolescents was chosen to provide a more conservative 
recommendation.91 The BMI cut-offs recommended by 
the Endocrine Society37 and recent Expert Committee 
Recommendations endorsed by the American Academy of 
Pediatrics3 are slightly more conservative recommending 
consideration of bariatric surgery when the BMI is greater 
than or equal to 50 kg/m2 or 40 kg/m2 with other comorbidities. 
In addition, the guidelines recommend that patients should be 
post pubertal or in late puberty and have attained near final 
adult stature. Patients and families should demonstrate the 
ability to comprehend the procedure and its risks; provide 
informed consent and/or assent; and be capable of adhering 
to the medical and nutritional postoperative plan. Consistent 
with recent guidelines, high risk adolescents with severe obe-
sity and medical comorbidities meeting these criteria, whose 
health deteriorates despite aggressive lifestyle intervention, 
may be considered for evaluation of bariatric surgery on an 
individualized basis with experts in this surgical specialty.
Identification and diagnosis 
of type 2 diabetes mellitus
There remains debate about the optimal strategy and frequency 
for testing for type 2 diabetes in youth at risk.92,93 Currently, 
the American Diabetes Association92 recommends testing 
children who are overweight (defined as having a BMI  85th 
percentile for age and sex, weight for height 85th percentile, 
or weight 120% of ideal for height) and have any 2 
additional risk factors including family history of type 2 
diabetes in a first or second degree relative; race/ethnicity of 
Native American, African-American, Latino, Asian American 
or Pacific Islander; signs of insulin resistance or conditions 
associated with insulin resistance such as acanthosis 
nigricans, hypertension, dyslipidemia, PCOS, or small for 
gestational age birth weight; and maternal history of diabetes 
or gestational diabetes during the child’s gestation. Testing is 
recommended to begin at age 10 years or at puberty if puberty 
occurs at a younger age and should be repeated every 3 years. 
Fasting plasma glucose is the preferred test. Three criteria can 
be used to establish the diagnosis of diabetes mellitus.92 These 
are (1) symptoms of diabetes such as polyuria, polydipsia 
or unexplained weight loss plus casual (random) plasma 
glucose concentration 200 mg/dL or (2) fasting plasma 
glucose 126 mg/dL or (3) plasma glucose 200 mg/dL 
at 2 hours during a standard oral glucose tolerance test. 
In the absence of unequivocal symptoms of hyperglycemia, 
confirmation on a second day is also recommended.92 
However, new recommendations from an International 
Expert Committee with representation from the American 
Diabetes Association, the European Association for the 
Study of Diabetes and International Diabetes Federation 
have proposed the use of HbA1c for diabetes diagnosis with 
a level at or above 6.5% considered diagnostic of diabetes.94 
The HbA1c should be repeated for confirmation unless there 
are symptoms of diabetes and a random plasma glucose 
level 200 mg/dL.94
Children with type 2 diabetes are typically overweight, 
have evidence of insulin resistance, and frequently have a 
family history of type 2 diabetes in a first- or second-degree 
relative.95 Children belonging to certain racial/ethnic groups, 
including Blacks and Hispanics, are also at higher risk.95 
However, the increasing prevalence of obesity in children7 
has made differentiating between type 1 and type 2 diabetes 
difficult at times.96 Children with phenotypic characteristics 
of type 2 diabetes may also have pancreatic autoimmunity,97,98 
and an increasing number of children with diabetes that 
require exogenous insulin at diagnosis are overweight.99 
A combination of clinical features, pancreatic autoantibodies, 
insulin level and c-peptide (beyond the acute presentation) 
may be needed to establish a diagnosis.93 Assigning an 
accurate diagnosis as soon as possible will facilitate 
implementation of the most appropriate management plan.
Management of type 2 diabetes 
mellitus
Type 2 diabetes is one of the most challenging complications 
of obesity presenting in childhood. In addition to the poten-
tially complex medical management that may be required, chil-
dren with type 2 diabetes are at high risk of depression,100,101 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 194
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which is associated with poor metabolic control.102 
Health-related quality of life is noted to be reduced in children 
with type 2 diabetes, who have lower health-related quality 
of life than children with type 1 diabetes in all domains 
and have the greatest impairment in emotional functioning 
and school functioning.103 Therefore, management of type 2 
diabetes in youth requires a team approach that ideally includes 
a physician, diabetes nurse educator, mental health speci-
alist, and nutritionist. Collaboration with the child’s school, 
including nursing and mental health specialists, provides 
additional support from staff who interact with the child 
daily.104
Lifestyle modification
Medical nutrition therapy is fundamental to the successful 
treatment of type 2 diabetes. As discussed previously for 
the management of obesity, a multidisciplinary approach 
is most likely to be successful. Using approaches that 
involve the whole family is also critical as adolescents 
with type 2 diabetes are likely to be from families who 
have type 2 diabetes and/or engage in high risk lifestyle 
behaviors.105 Both healthful dietary change and physical 
activity along with the appropriate psychosocial supports 
should be included in all management plans for children and 
adolescents with type 2 diabetes.92,95 Modest weight loss in 
overweight and obese adults106 and adolescents107 has been 
associated with reductions in insulin resistance. However, 
type 2 diabetes is a progressive disorder with ongoing loss of 
beta cell function over time such that only a small minority of 
adults are able to manage diabetes with lifestyle modification 
alone.95,108 While the rate of beta cell failure in children is 
unknown, some studies suggest that it may be even faster 
than in adults.109 A major question exists about whether early 
aggressive management of type 2 diabetes can slow the rate of 
beta cell failure and thereby improve long-term outcomes.110 
How aggressive therapy should be implemented is also an 
area of current debate and inquiry.110
Medical management
The optimal regimen or algorithm for medical management 
for type 2 diabetes in children is not clear. However, 
current guidelines from the American Diabetes Association 
recommend targeting treatment to achieve glycemic control 
with an HbA1c  7%.92 Studies of clinical populations in 
the US and UK have shown that most pediatric patients 
with type 2 diabetes are managed initially with insulin 
or metformin, alone or in combination.111,112 A recent 
report by Liberman et al, which drew data on 6 to 18 year 
olds from a commercially-insured population in the US, 
demonstrated that while metformin was the most commonly 
prescribed therapy, other antidiabetic agents were also being 
prescribed including sulfonylureas, insulin sensitizing agents 
(thiazolidinediones) and alpha-glucosidase inhibitors.113 
Table 3 summarizes the studies on medical management of 
type 2 diabetes in children described below.
Metformin
In the US, metformin is the only oral agent for treatment 
of type 2 diabetes that is approved for use in children (age 
10 years and older). Metformin’s primary action is to decrease 
hepatic glucose production and, secondarily, to increase 
insulin sensitivity in peripheral tissues. Jones et al conducted 
a double-blind, placebo-controlled study of metformin for 
management of type 2 diabetes in pediatric patients and 
demonstrated both safety and efficacy.114 In this study, 
82 children between the ages of 10 and 16 years with type 2 
diabetes were randomized to either 1000 mg of metformin 
twice daily or placebo for up to 16 weeks. Subjects receiving 
metformin had significantly better glycemic control measured 
by both fasting plasma glucose and HbA1c (7.5% vs 8.6%, 
P  0.001 at the last visit) compared to placebo without 
negative effects on body weight or lipids and comparable 
adverse events.114
Metformin is generally well tolerated. However, 
gastrointestinal side effects including abdominal discomfort, 
nausea and diarrhea occur in up to 50% of patients taking 
metformin, but discontinuation is uncommon.115 These side 
effects tend to decrease over time and can be minimized 
by a slow increase in dose and taking the medication with 
food. A very rare but serious side effect is lactic acidosis.116 
However, risk for lactic acidosis can be reduced by avoiding 
use of the medication in contraindicated circumstances,116 
which include renal impairment, hepatic dysfunction, 
congestive heart failure (unstable, in hospitalized patients, 
and/or with abnormal renal function),92 metabolic acidosis, 
and dehydration. Patients must also be advised to stop 
metformin with acute illnesses that place the patient at risk 
of dehydration, prior to surgeries when the patient must fast, 
or when the patient is having a radiographic study requiring 
iodinated contrast. A typical starting dose for metformin 
is 500 mg daily, which can be gradually increased weekly 
in 500 mg increments as needed and tolerated to a dose 
of 1000 mg twice daily, which is considered optimal.117 
Metformin is available as a liquid (Riomet® 500 mg/5 mL) 
for children, who are unable to swallow tablets, and in an 
extended release formulation. Metformin use is associated Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 195
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with decreased insulin resistance, limited weight gain and 
possible weight loss and, in some cases, modest improvement 
in lipid profiles.115,117 It can also improve ovulation in young 
women with polycystic ovarian syndrome.55 In addition to 
the low risk of hypoglycemia with metformin, these charac-
teristics have made metformin the first-line oral medication 
for overweight adults with type 2 diabetes.115
insulin therapy
Insulin is a frequently used therapy in type 2 diabetes 
management in children as it is one of the only two approved 
medical therapies. The major side effects associated with 
insulin therapy are hypoglycemia and weight gain. However, 
use of insulin is necessary at the time of diagnosis for 
children with severely uncontrolled diabetes or in addition to 
monotherapy with an oral agent (typically metformin) when 
target glycemic control is not achieved. Severely uncontrolled 
diabetes with evidence of catabolism is typically evidenced 
by an HbA1c  10%, fasting blood glucose 250 mg/dL, 
random blood glucose 300 mg/dL, ketonuria/ketoacidosis, 
or symptomatic diabetes with polyuria, polydipsia and weight 
loss.117 Use of short-term insulin therapy to reduce glucotoxicity 
may improve beta cell function.110 In a small study with 
18 adolescents, Sellers et al demonstrated that improvements 
in HbA1c following short-term (4 months) insulin therapy 
persisted up to 12 months without additional drug therapy.118
There are a number of insulin regimens available. 
They incorporate a combination of an intermediate-acting 
insulin (such as NPH) and/or a long-acting insulin (such 
as insulin detemir or insulin glargine) for basal coverage 
along with a short- or rapid-acting insulin (such as Regular, 
insulin aspart, insulin lispro, or insulin glulisine) to provide 
prandial glycemic coverage. Once the initial blood glucose 
levels have been stabilized, insulin can often be weaned 
as the dose of oral hypoglycemic medication is advanced. 
Whereas adolescents with type 1 diabetes may require 1 to 
1.5 U/kg/day of insulin,119 those with type 2 diabetes may 
require even greater doses of insulin because of insulin 
resistance. Different algorithms for the introduction of insulin 
and advancement of insulin have been suggested.117,120 When 
added to metformin therapy, beginning with a long-acting 
insulin, such as insulin glargine, given at bedtime may 
minimize the risk of hypoglycemia.120
Few studies have specifically evaluated the relationship 
of insulin and metformin in the management of pediatric 
type 2 diabetes.121,122 Zuhri-Yafi et al performed a retrospec-
tive review of 25 children with type 2 diabetes ranging in age 
from 8 to 15 years at diagnosis. Insulin (72%) or metformin 
(28%) were used as monotherapy at diagnosis depending on 
the severity of presentation. Only 5 of 18 patients started on 
insulin could be completely weaned to metformin, and 3 of 
these 5 then required reintroduction of insulin to maintain 
adequate glycemic control. Despite maximal dosing among 
the patients started on metformin monotherapy, 3 of 7 required 
the addition of another oral hypoglycemic (a sulfonylurea) 
by 6 months to maintain glycemic control.121 Kadmon et al 
conducted a retrospective review of 18 adolescents with 
an average age of 14.0 ± 1.9 years at diagnosis of whom 
11 were initially treated with insulin and then transitioned 
to metformin, and 7 were treated with metformin alone.122 
Glycemic control deteriorated when patients were transi-
tioned from insulin to metformin with an increase in average 
HbA1c from 5.0% to 8.4%. This was similar to control 
achieved with those initially managed with metformin alone 
although those with better compliance achieved better HbA1c 
results. Questionnaires completed prospectively by these 
patients indicated that those initially treated with insulin and 
transitioned to metformin may not view diabetes managed 
by pills alone to be as serious a disease as diabetes managed 
with insulin. These studies suggest that monotherapy with 
metformin may not be sufficient long-term therapy for youth 
with type 2 diabetes initially requiring insulin. However, 
these studies are small and retrospective. Larger, prospective 
studies are necessary to clarify whether these patterns apply 
more broadly to all youth with type 2 diabetes.
Other antihyperglycemic therapies 
and combination therapy
In adults with type 2 diabetes, after 3 years, only 50% are 
able to achieve target glycemic control with monotherapy.108 
However, little is known about the efficacy and safety of other 
antihyperglycemic therapies as monotherapy or combination 
therapy in youth with type 2 diabetes. As metformin and 
insulin are currently the only approved therapies for use in 
children, metformin combined with insulin is frequently the 
first choice for combination therapy.120,121
Beyond metformin, antihyperglycemic therapies can 
be divided into categories based on their mechanism of 
action. These include insulin sensitizers (thiazolidinediones); 
insulin secretagogues (sulfonylureas, meglitinides, incretin 
mimetics, DPP-IV inhibitors); glucosidase inhibitors (acarbose, 
miglitol); and amylin receptor agonists (pramlintide). None of 
these medications have approval in the US for the treatment 
of type 2 diabetes in children. Descriptions of the dosing, 
contraindications, side effects and monitoring of these 
medications are outlined in Table 4.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 197
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Despite the widespread use of metformin, few studies 
have actually been conducted in the pediatric population 
comparing metformin to other treatments for type 2 
diabetes. Gottschalk et al compared metformin 500 to 
1000 mg twice daily to glimepiride 1 to 8 mg once daily, a 
second-generation sulfonylurea, among 285 children with 
type 2 diabetes between the ages of 8 and 17 years. They 
found comparable reductions in HbA1c after 24 weeks (–0.7% 
with glimepiride vs –0.85% with metformin, P = 0.542) but 
greater weight gain with the glimepiride (1.97 kg vs 0.55 kg, 
P = 0.005).123 Overall, the proportion experiencing adverse 
events and clinically relevant hypoglycemia were similar 
in the two groups. Hyperglycemia and upper abdominal 
pain occurred in a greater proportion of subjects treated 
with glimepiride whereas other gastrointestinal complaints 
and headache occurred in a greater proportion treated 
with metformin.123 In the TODAY (Treatment Options for 
Type 2 Diabetes in Adolescents and Youth) study, a large 
multicenter, randomized parallel group trial, metformin 
alone is being compared to metformin with an intensive 
lifestyle intervention and metformin with rosiglitazone 
(a thiazolidinedione).124 Subjects in this study are between 10 
and 17 years of age with type 2 diabetes of at most 2 years’ 
duration. The primary outcome is time to treatment failure, 
defined as either HbA1c  8% for 6 months or inability 
to wean from temporary insulin therapy within 3 months 
following an acute metabolic decompensation.124 This study 
will inform the early management of type 2 diabetes in youth 
in terms of both the composition and intensity of therapy. 
Results of the study are expected in 2011.
Bariatric surgery
As discussed above,81 there is evidence to support the 
resolution of diabetes, ie, normalization of blood glucose 
levels in the absence of medications, in adolescents with 
type 2 diabetes who have undergone bariatric surgery. 
Adult studies suggest that the resolution rates are best with 
procedures that bypass portions of the small intestine.125 The 
American Diabetes Association recommends that bariatric 
surgery be considered in adults with a BMI  35 kg/m2 and 
type 2 diabetes especially if the diabetes is difficult to control 
with lifestyle and pharmacologic therapy.92 The additional 
issues that must be taken into consideration for children 
and adolescents with type 2 diabetes are discussed above.
Complications of diabetes
Children and adolescents with type 2 diabetes are at risk for 
microvascular and macrovascular complications.126,127 Due to 
the added threat of adiposity,127,128 youth with type 2 diabetes 
may present with higher rates of complications earlier in 
the disease process than youth with type 1 diabetes.129–131 
Therefore, more extensive screening is recommended at 
diagnosis.92 At diagnosis, screening should include a fasting 
lipid profile (once glycemic control has been achieved), urine 
microalbumin, and dilated eye examination.92 Subsequent 
eye examinations should be performed annually or less 
frequently following one or more normal examinations. 
Urine microalbumin should be performed annually. Two of 
three specimens collected in a 3- to 6-month period must be 
abnormal (30–299 µg/mg Cr) before assigning a diagnosis 
of microalbuminuria. Lipids should be monitored every 
2 years if normal and at least yearly if abnormal. Blood 
pressure should be checked at each visit. Guidelines for 
the management of dyslipidemia,132 hypertension,92 and 
albuminuria92 in youth with type 2 diabetes are available. 
Clinical symptoms of autonomic neuropathy should be 
reviewed annually,92 and a yearly foot examination is also 
recommended although the benefit in this age group has not 
clearly been established.95
Smoking, alcohol consumption, and pregnancy in 
adolescent girls can be additionally problematic for youth 
with type 2 diabetes and should be routinely addressed in 
clinical encounters. Smoking may increase the risk for micro-
albuminuria133 and contribute to the risk of macrovascular 
disease.134 Youth with type 2 diabetes should also receive 
routine dental care,135 annual influenza vaccination and, 
based on newly revised vaccine recommendations, children 
with diabetes age 2 years should receive a pneumococcal 
polysaccharide vaccination.92
Conclusion
In conclusion, obesity is an epidemic in childhood world-
wide, and the rates of type 2 diabetes in youth are rising in 
association. Treatment options for obesity, insulin resistance, 
metabolic syndrome and type 2 diabetes in youth include 
a comprehensive lifestyle modification plan and careful 
consideration of medical and/or surgical interventions. How-
ever, the data supporting available treatments remain limited. 
The treatment of obesity and related metabolic abnormalities 
in children is an area of intense scientific interest, ripe for fur-
ther investigation.
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